Drug
Edp 323 Dose Regimen 1
Edp 323 Dose Regimen 1: highest development phase Phase 2, developed by Enanta Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Enanta Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| EDP-323 Dose Regimen 1 NCT06170242 | Phase 2 | RSV Infection |
Latest
No recent events.
Follow Edp 323 Dose Regimen 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.